February 12, 2018
Audent Therapeutics starts dosing patients for rare pediatric disease Crigler-Najjar Syndrome, as it tests recently fast tracked AT342
Audentes Therapeutics has started with dosing of patients in a Phase 1/2 clinical trial of its product candidate AT342 for…